中国医药导报2024,Vol.21Issue(19) :46-50.DOI:10.20047/j.issn1673-7210.2024.19.09

ARHGDIB在恶性肿瘤中的研究进展

Research progress of ARHGDIB in malignant tumors

张婧萱 乔媛 王婷婷 赵建国 宝莹娜
中国医药导报2024,Vol.21Issue(19) :46-50.DOI:10.20047/j.issn1673-7210.2024.19.09

ARHGDIB在恶性肿瘤中的研究进展

Research progress of ARHGDIB in malignant tumors

张婧萱 1乔媛 1王婷婷 1赵建国 1宝莹娜1
扫码查看

作者信息

  • 1. 内蒙古医科大学附属医院放疗科,内蒙古呼和浩特 010030
  • 折叠

摘要

侵袭和转移是恶性肿瘤难以治疗的重要因素,ARHGDIB参与多种恶性肿瘤的侵袭和转移,是一类具有重要作用的转移抑制剂.本文阐述ARHGDIB通过调节RhoGTP酶参与多种信号通路,调控恶性肿瘤的侵袭和转移.ARHGDIB在膀胱癌、胃癌及白血病中主要通过Rac通路发挥作用,而在肺癌、肝癌和胰腺导管腺癌中,其对PI3K/PKB/Akt信号通路的调控较常见.ARHGDIB通过调控肿瘤微环境中的炎症反应抑制恶性肿瘤的转移,因此,其在不同恶性肿瘤中可通过调控不同信号通路发挥作用.

Abstract

Invasion and metastasis are important factors that make malignant tumors difficult to treat.ARHGDIB is involved in invasion and metastasis of various malignant tumors and is a class of important metastasis inhibitors.This article elaborates on involvement of ARHGDIB in multiple signaling pathways by regulating Rho GTPase,regulating invasion and metastasis of malignant tumors.ARHGDIB plays a role mainly through Rae pathway in bladder cancer,gastric cancer,and leukemia,while in lung cancer,liver cancer,and pancreatic ductal adenocarcinoma,its regulation of PI3K/PKB/Akt signaling pathway is more common.ARHGDIB inhibits metastasis of malignant tumors by regulating inflammatory response in tumor microenvironment.Therefore,it can play a role in different malignant tumors by regulating different signaling pathways.

关键词

ARHGDIB/恶性肿瘤/转移/Rho/GTP酶

Key words

ARHGDIB/Malignant tumor/Metastasis/Rho GTPase

引用本文复制引用

基金项目

内蒙古自治区自然科学基金项目(2019MS08124)

内蒙古自治区科技计划项目(2019GG150)

内蒙古医科大学面上项目(YKD2021MS032)

出版年

2024
中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
段落导航相关论文